Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Cited by (1,000)

Items 201–300 of 1,000

1. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
   Luping Lin, Saurabh Asthana, Elton Chan, Sourav Bandyopadhyay, Maria M. Martins, Victor R. Olivas, Jenny Jiacheng Yan, Luu Q. Pham, Mingxue Michelle Wang, Gideon E. Bollag et al. · 2014 · Proceedings of the National Academy of Sciences
2. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
   Kenta Masui, Beatrice Gini, J. Wykosky, Ciro Zanca, Paul S. Mischel, Frank B. Furnari, Webster K. Cavenee · 2013 · Carcinogenesis
3. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
   Soundararajan, Rama, Fradette, Jared, Konen, Jessica, Moulder, Stacy, Zhang, Xiang, Gibbons, Don, Varadarajan, Navin, Wistuba, Ignacio, Tripathy, Debasish, Bernatchez, Chantale et al. · 2019 · Cancers
4. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers
   Laetitia Seguin, Maria F. Camargo, Hiromi Inoue Wettersten, Shumei Kato, Jay S. Desgrosellier, Tami Von Schalscha, Kathryn C. Elliott, Erika C. Cosset, Jacqueline Lesperance, Sara M. Weis et al. · 2017 · Cancer Discovery
5. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3
   Jinnan Yue, Dacheng Lv, Caiyun Wang, Ling Li, Qingnan Zhao, Hongzhuan Chen, Lu Xu · 2018 · Oncogene
6. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
   Elena Ghiso, Cristina Migliore, Vito Ciciriello, Elena Morando, Annalisa Petrelli, Simona Corso, Emmanuele De Luca, Gaia Gatti, Marco Volante, Silvia Giordano · 2017 · Neoplasia
7. Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
   Yukie Kashima, Daisuke Shibahara, Ayako Suzuki, Kyoko Muto, Ikei S. Kobayashi, David O. Plotnick, Hibiki Udagawa, Hiroki Izumi, Yuji Shibata, Kosuke Tanaka et al. · 2021 · Cancer Research
8. Epithelial-mesenchymal transition
   Cecilia Xi Zhang, Ruby Yun‐Ju Huang, Guojun Sheng, Jean Paul Thiery · 2025 · Cell
9. Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
   Wen Gao, Michael L. Wang, Li Wang, Haibo Lu, Shuhong Wu, Bingbing Dai, Zhishuo Ou, Liang Zhang, John Victor Heymach, Kathryn Ann Gold et al. · 2014 · JNCI Journal of the National Cancer Institute
10. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
    Houssein Chhouri, David Alexandre, Luca Grumolato · 2023 · Cancers
11. β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer
    Cong Xu, Zebo Jiang, Le Shao, Ziming Zhao, Xing‐Xing Fan, Xinbing Sui, Lili Yu, Xuan‐Run Wang, Ruonan Zhang, Wenjun Wang et al. · 2023 · Pharmacological Research
12. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
    Gong, Ke, Guo, Gao, Gerber, David E., Gao, Boning, Peyton, Michael, Huang, Chun, Minna, John D., Hatanpaa, Kimmo J., Kernstine, Kemp, Cai, Ling et al. · 2018 · Journal of Clinical Investigation
13. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
    Neel, Dana S., Bivona, Trever G. · 2017 · npj Precision Oncology
14. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
    Anthonie J. van der Wekken, Ali Saber, T. Jeroen N. Hiltermann, Klaas Kok, A. van den -->Berg, Harry J.M. Groen · 2016 · Critical Reviews in Oncology/Hematology
15. TAM family kinases as therapeutic targets at the interface of cancer and immunity
    Deborah DeRyckere, Justus M. Huelse, Henry Shelton Earp, Douglas K. Graham · 2023 · Nature Reviews Clinical Oncology
16. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers
    Kavitha Balaji, Smruthi Vijayaraghavan, Lixia Diao, Pan Tong, You-Hong Fan, Jason P.W. Carey, Tuyen N. Bui, Steve L. Warner, John Victor Heymach, Kelly K. Hunt et al. · 2016 · Molecular Cancer Research
17. INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
    Beekhof, Robin, van Alphen, Carolien, Henneman, Alex A, Knol, Jaco C, Pham, Thang V, Rolfs, Frank, Labots, Mariette, Henneberry, Evan, Le Large, Tessa YS, de Haas, Richard R et al. · 2019 · Molecular Systems Biology
18. TAM Receptor Tyrosine Kinases in Cancer Drug Resistance
    Mikaella Vouri, Sassan Hafizi · 2017 · Cancer Research
19. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
    Donghwa Kim, Duc‐Hiep Bach, Yanhua Fan, Thi-Thu-Trang Luu, Ji‐Young Hong, Hyen Joo Park, Sang Kook Lee · 2019 · Cell Death and Disease
20. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
    Song, Kyung-A, Niederst, Matthew J., Lochmann, Timothy L., Hata, Aaron N., Kitai, Hidenori, Ham, Jungoh, Floros, Konstantinos V., Hicks, Mark A., Hu, Haichuan, Mulvey, Hillary E. et al. · 2018 · Clinical Cancer Research
21. EGFR mutations in lung cancer: from tissue testing to liquid biopsy
    Francesca Fenizia, Antonella De Luca, Raffaella Pasquale, Alessandra Sacco, Laura Forgione, Matilde Lambiase, Alessia Iannaccone, Nicoletta Chicchinelli, Renato Franco, Antônio Rossi et al. · 2015 · Future Oncology
22. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
    Maria Lie Lotsberg, Katarzyna Wnuk-Lipińska, Stéphane Terry, Tuan Zea Tan, Ning Lü, Laura Trachsel-Moncho, Gro Vatne Røsland, Muntequa Ishtiaq Siraji, Monica Hellesøy, Austin J. Rayford et al. · 2020 · Journal of Thoracic Oncology
23. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer
    Mai Tanaka, Dietmar W. Siemann · 2021 · International Journal of Molecular Sciences
24. Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
    Xueda Hu, Zemin Zhang · 2015 · Trends in Genetics
25. Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting
    Antonella Sistigu, Francesca Di Modugno, Gwenola Manic, Paola Nisticò · 2017 · Cytokine & Growth Factor Reviews
26. S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
    Mike F. Burbridge, Céline J. Bossard, Carine Saunier, Imre Fejes, Alain Bruno, Stéphane Léonce, Gilles Ferry, Georges Da Violante, François Bouzom, Valérie Cattan et al. · 2013 · Molecular Cancer Therapeutics
27. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells
    Haiying Cheng, Zhenfeng Zhang, Ruth Rodriguez Barrueco, Alain Borczuk, Huijie Liu, Jiyang Yu, José M. Silva, Simon K. Cheng, Roman Perez-Soler, Balázs Halmos · 2015 · Oncotarget
28. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
    Gong, Ke, Guo, Gao, Panchani, Nishah, Bender, Matthew E., Gerber, David E., Minna, John D., Fattah, Farjana, Gao, Boning, Peyton, Michael, Kernstine, Kemp et al. · 2020 · Nature Cancer
29. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
    Agnete S. T. Engelsen, Maria Lie Lotsberg, Raefa Abou Khouzam, Jean Paul Thiery, James B. Lorens, Salem Chouaı̈b, Stéphane Terry · 2022 · Frontiers in Immunology
30. Hippo and TGF-β interplay in the lung field
    Akira Saito, Takeshi Nagase · 2015 · American Journal of Physiology-Lung Cellular and Molecular Physiology
31. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
    Xuejin Ou, Ge Gao, Inbar A Habaz, Yongsheng Wang · 2024 · MedComm
32. Epithelial Mesenchymal Transition in Aggressive Lung Cancers
    Vivek Mittal · 2015 · Advances in experimental medicine and biology
33. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
    Gregory J. Riely, Helena Alexandra Yu · 2015 · Clinical Cancer Research
34. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
    Alejandro Vázquez‐Martín, Sílvia Cufí, Cristina Oliveras‐Ferraros, Violeta Zenobia Torres-Garcia, Bruna Corominas-Faja, Elisabet Cuyàs, Rosa Bonavia, Joana Visa, Begoña Martı́n-Castillo, Enrique Barrajón‐Catalán et al. · 2013 · Scientific Reports
35. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers
    Chen Chen, Wei-Ran Liu, Bin Zhang, Lian-Min Zhang, Chenguang Li, Chang Liu, Hua Zhang, Yansong Huo, Yu-Chen Ma, Pengfei Tian et al. · 2020 · Cancer Letters
36. Prognostic and predictive biomarkers in lung cancer. A review
    Erik Thunnissen, Kimberly Van der Oord, Michael den Bakker · 2014 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
37. ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer
    Jun Hong, Dunfa Peng, Zheng Chen, Vikas Sehdev, Abbes Belkhiri · 2012 · Cancer Research
38. Drug Resistance to EGFR Inhibitors in Lung Cancer
    Osamu Tetsu, Matthew J. Hangauer, Janyaporn Phuchareon, David W. Eisele, Frank P. McCormick · 2016 · Chemotherapy
39. Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
    Caicun Zhou, Luan Di Yao · 2015 · Journal of Thoracic Oncology
40. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma
    Manuela Schmidinger, Romano Danesi · 2017 · The Oncologist
41. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
    Yumi Yokoyama, Erin Denise Lew, Ruth Seelige, Elizabeth A. Tindall, Colin T. Walsh, Patrick C. Fagan, Jack Y. Lee, Robin Nevarez, Joanne Oh, Kathleen D. Tucker et al. · 2019 · Cancer Research
42. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells
    Kei Namba, Kazuhiko Shien, Yuta Takahashi, Hidejiro Torigoe, Hiroki Sato, Takahiro Yoshioka, Tatsuaki Takeda, Eisuke Kurihara, Yusuke Ogoshi, Hiromasa Yamamoto et al. · 2018 · Molecular Cancer Research
43. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Fang Wu, Junhe Li, Changchen Jang, Janfeng Wang, Jianping Xiong · 2014 · PubMed Central
44. Emerging Roles of SIRT1 in Cancer Drug Resistance
    Z. Wang, Wenyong Chen · 2013 · Genes & Cancer
45. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
    Yufang Ma, Nan Tang, Reid C. Thompson, Bret C. Mobley, Steven W. Clark, Jann Nagina Sarkaria, Jialiang Wang · 2015 · Clinical Cancer Research
46. Therapeutic targeting of the functionally elusive TAM receptor family
    Yu Rebecca Miao, Erinn B. Rankin, Amato J. Giaccia · 2023 · Nature Reviews Drug Discovery
47. Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
    Clémence Feneyrolles, Aurélia Spenlinhauer, Léa Guiet, Bénédicte Fauvel, Bénédicte Daydé-Cazals, Pierre Warnault, Gwénaël Chevé, Abdelaziz Yasri · 2014 · Molecular Cancer Therapeutics
48. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
    Niki Karachaliou, Imane CHAIB-OUKADOUR, Andrés Felipe Cardona, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Jie Yang, Xueting Cai, Zhigang Wang, Chunping Hu, Ana Drozdowskyj et al. · 2018 · EBioMedicine
49. Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
    Tatiana Shaurova, Letian Zhang, David W. Goodrich, Pamela A. Hershberger · 2020 · Frontiers in Genetics
50. Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
    Jing Wang, Natalie W. Pursell, Maria Samson, Ruzanna Atoyan, Anna W. Ma, Abdelkader Selmi, Wanlu Xu, Xiong Cai, Maurizio Voi, Pierre Savagner et al. · 2013 · Molecular Cancer Therapeutics
51. The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis
    Hui Li, Fangying Xu, Si Li, Anjing Zhong, Xianwen Meng, Maode Lai · 2016 · Cell Adhesion & Migration
52. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
    Yoko Tsukita, Naoya Fujino, Eisaku Miyauchi, Ryoko Saito, Fumiyoshi Fujishima, Koji Itakura, Yorihiko Kyogoku, Koji Okutomo, Mitsuhiro Yamada, Tatsuma Okazaki et al. · 2019 · Molecular Cancer
53. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer
    Ningning Cheng, Xuefei Li, Chao Zhao, Shengxiang Ren, Xiaoxia Chen, WEIJING CAI, Mingchuan Zhao, YISHI ZHANG, JIAYU LI, QI WANG et al. · 2014 · Oncology Reports
54. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
    Juliano D. Paccez, Kristal Duncan, Durairaj Sekar, Ricardo G. Correa, Yihong Wang, Xuesong Gu, Manoj Bashin, Kelly Chibale, Towia A. Libermann, Luiz Fernando Zerbini · 2019 · Oncogenesis
55. A Live-Cell Screen for Altered Erk Dynamics Reveals Principles of Proliferative Control
    Alexander G. Goglia, Maxwell Z. Wilson, Siddhartha G. Jena, Jillian Silbert, Lena P. Basta, Danelle Devenport, Jared E. Toettcher · 2020 · Cell Systems
56. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
    Martha Wium, Aderonke F. Ajayi-Smith, Juliano D. Paccez, Luiz Fernando Zerbini · 2021 · Cancers
57. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer
    Matin Shaikh, Yashodeep Shinde, Rahul H. Pawara, Malleshappa N. Noolvi, Sanjay Javerilal Surana, Iqrar Ahmad, Harun Patel · 2021 · Journal of Medicinal Chemistry
58. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
    Jacques L. Cadranel, Anne-Marie Ruppert, Michèle Beau‐Faller, Marie Wislez · 2013 · Critical Reviews in Oncology/Hematology
59. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
    Luping Lin, Trever Grant Bivona · 2012 · Chemotherapy Research and Practice
60. Targeted therapies in development for non-small cell lung cancer
    Grace Kho Dy, Thanyanan Reungwetwattana · 2013 · Journal of Carcinogenesis
61. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
    Christian Diego Rolfo, Elisa Giovannetti, David S. Hong, Trever Grant Bivona, Luis Estuardo Raez, Giuseppe Bronte, Lucio Buffoni, Noemı́ Reguart, Edgardo S. Santos, Paul R. Germonpré et al. · 2014 · Cancer Treatment Reviews
62. Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
    Piergiorgio Pettazzoni, Andrea Viale, Parantu K. Shah, Alessandro Carugo, Haoqiang Ying, Huamin Wang, Giannicola Genovese, Sahil Seth, Rosalba Minelli, Tessa Green et al. · 2015 · Cancer Research
63. mTOR Signaling Confers Resistance to Targeted Cancer Drugs
    Yakir Guri, Michael N. Hall · 2016 · Trends in cancer
64. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
    Stéphane Terry, Abdérémane Abdou, Agnete S. T. Engelsen, Stéphanie Buart, Philippe Dessen, Stéphanie Corgnac, Davi Collares, Guillaume Meurice, Gro Gausdal, Véronique Baud et al. · 2019 · Cancer Immunology Research
65. Polarization of tumor-associated macrophages and Gas6/Axl signaling in oral squamous cell carcinoma
    Kuo‐Chou Chiu, Chien-Hsing Lee, Shyun-Yeu Liu, Yu‐Ting Chou, Ren‐Yeong Huang, Shih‐Ming Huang, Yi‐Shing Shieh · 2015 · Oral Oncology
66. MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines
    Fei Meng, Fengfeng Wang, Lili Wang, Sze Chuen Cesar Wong, William Chi Shing Cho, Lawrence Chan · 2016 · Frontiers in Genetics
67. AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
    Marie-Anne Goyette, Jean‐François Côté · 2022 · Cancers
68. Stem cell-like ALDH bright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
    Bruna Corominas-Faja, Cristina Oliveras‐Ferraros, Elisabet Cuyàs, Antonio Segura‐Carretero, Jorge Joven, Begoña Martı́n-Castillo, Enrique Barrajón‐Catalán, Vicente Micol, Joaquim Bosch‐Barrera, Javier Abel Menéndez · 2013 · Cell Cycle
69. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
    Jin Rong Zhou, Zhong Wu, Gabrielle S. Wong, Eirini Pectasides, Ankur K. Nagaraja, Matthew D. Stachler, Haikuo Zhang, Ting Chen, Haisheng Zhang, Jie Bin Liu et al. · 2017 · Nature Communications
70. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
    Jianzhong Lin, Zengjun Wang, Wei De, Ming Zheng, Weizhang Xu, Hongfei Wu, Alex Armstrong, Jiageng Zhu · 2017 · Oncotarget
71. Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
    Helena Alexandra Yu, Gregory J. Riely, Christine Marie Lovly · 2014 · Clinical Cancer Research
72. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
    Sílvia Cufí, Rosa Bonavia, Alejandro Vázquez‐Martín, Cristina Oliveras‐Ferraros, Bruna Corominas-Faja, Elisabet Cuyàs, Begoña Martı́n-Castillo, Enrique Barrajón‐Catalán, Joana Visa, Antonio Segura‐Carretero et al. · 2013 · Scientific Reports
73. Acquisition of cancer stem cell‐like properties in non‐small cell lung cancer with acquired resistance to afatinib
    Shinsuke Hashida, Hiromasa Yamamoto, Kazuhiko Shien, Yuichiro Miyoshi, Tomoaki Ohtsuka, Ken Suzawa, Mototsugu Watanabe, Yuho Maki, Junichi Soh, Hiroaki Asano et al. · 2015 · Cancer Science
74. ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
    Amir Ata Saei, Christian Michel Beusch, Alexey L. Chernobrovkin, Pierre Sabatier, Bo Zhang, Ülkü Güler, Eleni Stergiou, Massimiliano Gaetani, Ákos Végvári, Roman A. Zubarev · 2019 · Nature Communications
75. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
    Yang Wang, Hongping Xia, Zhixiang Zhuang, Liyun Miao, X Chen, Hourong Cai · 2014 · Cell Death and Disease
76. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
    Sarah K. Nelson-Taylor, Anh Tuan Le, Minjae Yoo, Laura Schubert, Katie M. Mishall, Andrea E. Doak, Marileila Varella‐Garcia, Aik Choon Tan, Robert Charles Doebele · 2017 · Molecular Cancer Therapeutics
77. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
    Pınar Kanlikilicer, Bülent Özpolat, Burcu Aslan, Recep Bayraktar, Nilgün Gürbüz, Cristian Rodriguez‐Aguayo, Emine Bayraktar, Merve Denizli, Vianey González-Villasana, Cristina Ivan et al. · 2017 · Molecular Therapy — Nucleic Acids
78. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
    Song Yi Bae, Ji‐Young Hong, Hyejung Lee, Hyen Joo Park, Sang Kook Lee · 2015 · Oncotarget
79. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
    Villaflor, Victoria, Won, Brian, Nagy, Rebecca, Banks, Kimberly, Lanman, Richard B., Talasaz, AmirAli, Salgia, Ravi · 2016 · Oncotarget
80. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation
    Ji Hye Kim, Boas Nam, Yun Jung Choi, Seon Ye Kim, Jungeun Lee, Ki Jung Sung, Woo Sung Kim, Chang‐Min Choi, Eun‐Ju Chang, Jae Soo Koh et al. · 2018 · Cancer Research
81. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
    Hanjie Yu, Ruibin Liu, Binyun Ma, Xiaolei Li, H-y Yen, Yue Zhou, Valery G. Krasnoperov, Z Xia, Xueyuan Zhang, Alfredo Maria Bove et al. · 2015 · British Journal of Cancer
82. The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma
    Monika A. Cichoń, Zsófia Szentpétery, Matthew P. Caley, E S Papadakis, Ian Campbell Mackenzie, Caroline H. Brennan, Edel A. O’Toole · 2013 · Oncogene
83. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer
    Qin Guo, Tanja Grimmig, Gabriel González, Anita Giobbie‐Hurder, Gretchen Berg, Nolan Carr, Brian J. Wilson, Pallavi Banerjee, Jie Ma, Jason S. Gold et al. · 2018 · Journal of Biological Chemistry
84. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors
    Sai Li, Yanfang Zhao, Kewen Wang, Yali Gao, Jianming Han, Bingbing Cui, Ping Gong · 2013 · Bioorganic & Medicinal Chemistry
85. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma
    Maity, Tapan K., Venugopalan, Abhilash, Linnoila, Ilona, Cultraro, Constance M., Giannakou, Andreas, Nemati, Roxanne, Zhang, Xu, Webster, Joshua D., Ritt, Daniel, Ghosal, Sarani et al. · 2015 · Cancer Discovery
86. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance
    Xu Zhang, Tapan Kumar Maity, Karen E. ROSS, Yue Andy Qi, Constance M. Cultraro, Meriam Bahta, Stephanie C. Pitts, Meghana Keswani, Shaojian Gao, Khoa Dang P. Nguyen et al. · 2021 · Cancer Research
87. EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
    Hee-Jeong Choi, Yoo Joo Jeong, Jieun Kim, Hyang‐Sook Hoe · 2023 · Frontiers in Pharmacology
88. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
    Wonjun Ji, Chang‐Min Choi, Jin Kyung Rho, Se Jin Jang, Young Soo Park, Sung‐Min Chun, Woo Sung Kim, Jung‐Shin Lee, Sang‐We Kim, Dae Ho Lee et al. · 2013 · BMC Cancer
89. BCL6 promotes glioma and serves as a therapeutic target
    Liang Xu, Ye Chen, Marina Dutra‐Clarke, Anand Mayakonda, Masaharu Hazawa, Steve E. Savinoff, Ngan Doan, JONATHAN W. SAID, William H. Yong, Ashley Watkins et al. · 2017 · Proceedings of the National Academy of Sciences
90. Adaptive stress signaling in targeted cancer therapy resistance
    Evangelos Pazarentzos, Trever Grant Bivona · 2015 · Oncogene
91. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
    Pei‐Chih Lee, Yueh‐Fu Fang, Hirohito Yamaguchi, Wei‐Jan Wang, Tse-Ching Chen, Xuan Hong, Baozhen Ke, Weiya Xia, Yongkun Wei, Zhengyu Zha et al. · 2018 · Cancer Cell
92. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
    Julia Boshuizen, Nora Pencheva, Oscar Krijgsman, Daniela M. D'Empaire Altimari, Patricia Garrido Castro, Beaunelle de Bruijn, Maarten Alexander Ligtenberg, Elke Gresnigt-Van den Heuvel, David W. Vredevoogd, Ji‐Ying Song et al. · 2021 · Cancer Research
93. Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
    Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang · 2022 · Oncology Letters
94. MET/HGF pathway activation as a paradigm of resistance to targeted therapies
    Brian Ko, Tianfang He, Shirish M. Gadgeel, Balázs Halmos · 2017 · Annals of Translational Medicine
95. Axl inhibitors as novel cancer therapeutic agents
    Yingying Shen, Xiguang Chen, Jun He, Duan‐Fang Liao, Xuyu Zu · 2018 · Life Sciences
96. Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility
    Min Yu, Wenjing Li, Qianqian Wang, Yan Wang, Fei Lu · 2018 · Oncogene
97. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
    Donatella Romaniello, Luigi Mazzeo, Maicol Mancini, Ilaria Marrocco, Ashish Noronha, Matthew Kreitman, Swati Srivastava, Soma Ghosh, Moshit Lindzen, Tomer‐Meir Salame et al. · 2018 · Clinical Cancer Research
98. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells
    Jun Wang, Oliver R. Mikse, Rachel G. Liao, Yvonne Y. Li, Li Tan, Pasi Antero Janne, Nathanael S. Gray, Kwok‐Kin Wong, Peter S. Hammerman · 2014 · Oncogene
99. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery
    Appaji Dokala, Suman Siddharth Thakur · 2016 · Oncogene
100. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase
     K.S. Gajiwala, Neil B. Grodsky, Ben Bolaños, Junli Feng, Rose Ann Ferre, Sergei L. Timofeevski, Meirong Xu, Brion William Murray, Ted W. Johnson, Albert Stewart · 2017 · Journal of Biological Chemistry